Clinical/translation signal: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
ClinicalTrials.gov registry update for A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Ye...
SourceClinicalTrials.govClinical trial registry updates are translation signals, not commercialization claims by themselves.
SourceClinicalTrials.govClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.
SourceClinicalTrials.govNo reviewed person relationship is attached to this event.
No reviewed topic relationship is attached to this event.
No reviewed problem relationship is attached to this event.
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Fol...